- Home
- NRXP vs MOLN Comparison
NRXP vs MOLN Comparison
Compare NRXP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXP | MOLN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 170.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXP | MOLN |
|---|---|---|
| Price | $3.47 | $4.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $38.25 | $8.38 |
| AVG Volume (30 Days) | ★ 790.1K | 1.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,000.00 | N/A |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $3.53 |
| 52 Week High | $5.06 | $5.36 |
Technical Indicators
Market Signals| Indicator | NRXP | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 53.74 |
| Support Level | $3.45 | $4.13 |
| Resistance Level | $3.62 | $4.51 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 46.67 | 46.67 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.